| PD-1/PD-L1抑制剂联合抗血管生成药物治疗晚期三阴性乳腺癌的研究进展 |
| |
| 引用本文： | 黄世芬,令晓玲. PD-1/PD-L1抑制剂联合抗血管生成药物治疗晚期三阴性乳腺癌的研究进展[J]. 肿瘤防治研究, 2021, 48(1): 75-81. DOI: 10.3971/j.issn.1000-8578.2021.20.0615 |
| |
| 作者姓名： | 黄世芬 令晓玲 |
| |
| 作者单位： | 1. 730000 兰州，兰州大学第一临床医学院；2. 730000 兰州，兰州大学第一医院肿瘤内科；3. 730000 兰州，甘肃省生物治疗与再生医学重点实验室；4. 730000 兰州，兰州大学第一医院东岗院区肿瘤科 |
| |
| 基金项目： | 甘肃省生物治疗与再生医学重点实验室资助项目（zdsyskfkt-201706）（临床研究注册号ChiCRTOIC-16008894）；兰州市科技局资助项目（2019-ZD-42） |
| |
| 摘 要： | 晚期三阴性乳腺癌较其他亚型乳腺癌的治疗手段少、生存期短、预后差.近年飞速发展的免疫治疗有望延长晚期三阴性乳腺癌的生存时间,但是多项临床研究提示PD-1/PD-L1抑制剂单药治疗晚期三阴性乳腺癌有效率低.新近研究显示抗血管生成药物的治疗不仅可以使血管正常化,抑制肿瘤生长,还可以增强免疫治疗的疗效,与PD-1/PD-L1抑...
|
| 关 键 词： | 晚期三阴性乳腺癌 PD-1/PD-L1抑制剂 抗血管生成药物 |
| 收稿时间： | 2020-06-05 |
Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors inTreatment of Advanced Triple-negative Breast Cancer |
| |
| HUANG Shifen,LING Xiaoling. Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors inTreatment of Advanced Triple-negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 75-81. DOI: 10.3971/j.issn.1000-8578.2021.20.0615 |
| |
| Authors: | HUANG Shifen LING Xiaoling |
| |
| Affiliation: | 1. First Clinical Medical College of Lanzhou University, Lanzhou 730000, China; 2. Department of Oncology, The First Hospital of Lanzhou University, Lanzhou 730000, China; 3. Gansu Province Key Laboratory of Biotherapy and Regenerative Medicine, Lanzhou 730000, China; 4. Department of Oncology, Donggang Hospital, The First Hospital of Lanzhou University, Lanzhou 730000, China |
| |
| Abstract: | Advanced triple-negative breast cancer(TNBC) has less treatments, shorter survival time and poorer prognosis than other subtypes of breast cancer. The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced TNBC patients, but multiple clinical studies have suggested that PD-1/PD-L1 inhibitor monotherapy have a low efficiency in the treatment of advanced TNBC. Recent studies have shown that the treatment with angiogenesis inhibitors can not only normalize blood vessels and inhibit tumor growth, but also enhance the efficacy of immunotherapy. Angiogenesis inhibitors combined with PD-1/PD-L1 inhibitors have synergistic effects. This article analyzes the mechanism of PD-1/PD-L1 inhibitors and angiogenesis inhibitors, reviews the preclinical and clinical studies on the combination of two types of drugs in the treatment of advanced TNBC and summarizes their efficacy and safety, to provide new perspectives and ideas for the treatment strategy of advanced TNBC. |
| |
| Keywords: | Advanced triple-negative breast cancer PD-1/PD-L1 inhibitors Angiogenesis inhibitors |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
